Cassava Sciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
A director at Cassava Sciences Inc. acquired 8,600 shares of common stock at $2.90 per share, signaling confidence.
Cassava Sciences' President and CEO, Richard Barry, reported a transaction involving the purchase of 150,000 shares of common stock at an average price of $2.76, though the reported transaction date is in the future.
Cassava Sciences' President and CEO, Richard Barry, plans to purchase 73,385 shares of common stock at an average price of $2.75 per share on November 19, 2025.
Cassava Sciences Inc. Director Dawn Carter Bir was granted 53,000 stock options with an exercise price of $3.98, vesting over three years.
Cassava Sciences' Chief Operating & Legal Officer, Robert Christopher Cook, acquired 13,725 shares of common stock at $2.91 per share.
Cassava Sciences President and CEO, Richard Barry, acquired 7,172 shares of common stock through a trust at an average price of $2.28 per share.
Cassava Sciences' President and CEO, Barry Richard, acquired over 237,000 shares of common stock through trust accounts in mid-September 2025.
Cassava Sciences Inc. Director Patrick J. Scannon, MD PhD, was granted 26,500 stock options with an exercise price of $2.11, vesting over one year.
Cassava Sciences Inc. Director Robert Eugene Anderson Jr. was granted 26,500 stock options as part of the company's amended non-employee director compensation program, approved by stockholders on May 23, 2025.
Cassava Sciences Inc. Director Pierre Gravier was granted 26,500 stock options with an exercise price of $2.11, vesting over one year, as part of the company's amended non-employee director compensation program.
Cassava Sciences Inc. Director Robert Z. Gussin was granted 26,500 stock options with an exercise price of $2.11, effective May 23, 2025, as part of the company's amended non-employee director compensation program.
Cassava Sciences Inc. Director Claude Nicaise was granted 26,500 stock options with an exercise price of $2.11, vesting monthly over one year, as part of the company's amended non-employee director compensation program.
Cassava Sciences Inc. Director Michael J. O'Donnell was granted 26,500 stock options with an exercise price of $2.11, vesting over one year, as part of the company's amended non-employee director compensation program.
Chief Financial Officer Eric Schoen of Cassava Sciences Inc. reports the acquisition of stock options.
Richard Barry, President & CEO of Cassava Sciences, acquired 350,000 stock options on April 17, 2025, according to a Form 4 filing with the SEC.
Freda Nassif, Chief Business Officer of Cassava Sciences, was granted stock options for 100,000 shares on April 17, 2025, vesting annually over four years.
Robert Christopher Cook, Chief Operating & Legal Officer of Cassava Sciences, was granted stock options for 100,000 shares on April 17, 2025.
Cassava Sciences' Chief Medical Officer, James William Kupiec, sold 4,000 shares of common stock on November 29, 2024.
Cassava Sciences' Chief Financial Officer, Eric Schoen, exercised stock options and sold shares on November 29, 2024.
A Cassava Sciences executive, Jaren Landen, was granted 85,000 stock options on November 18, 2024, which vest over four years.
Freda Nassif, Chief Commercial Officer of Cassava Sciences, was granted 100,000 stock options on November 18, 2024.
Richard Barry, President & CEO of Cassava Sciences, was granted 600,000 stock options on October 1, 2024, according to a Form 4 filing.
Eric Schoen, CFO of Cassava Sciences, reports the acquisition of 100,000 stock options.
Robert Christopher Cook, SVP & General Counsel of Cassava Sciences, reports the acquisition of stock options.
James William Kupiec, Chief Medical Officer of Cassava Sciences, was granted stock options for 100,000 shares on September 6, 2024.
Remi Barbier, President and CEO of Cassava Sciences, was granted stock options for 50,000 shares on May 20, 2024.
Eric Schoen, CFO of Cassava Sciences, reports the acquisition of stock options.
Robert Christopher Cook, SVP & General Counsel of Cassava Sciences, was granted stock options for 10,000 shares on May 20, 2024.
James William Kupiec, Chief Medical Officer of Cassava Sciences, was granted stock options for 10,000 shares on May 20, 2024.
Form 4: Cassava Sciences Director Sanford Robertson Reports Gift of Shares and Acquisition by Spouse
Director Sanford Robertson reported gifting 5,000 shares of Cassava Sciences stock and his spouse acquiring 5,000 shares.